MEA RNAi Drug Delivery Market

MEA RNAi Drug Delivery Market Size ( 2024 to 2029)

The size of the MEA RNAi Drug Delivery market is estimated to reach USD 22.55 billion by 2029 from a market value of USD 8.05 billion in 2024, at a CAGR of 22.88%.

RNAi Drug Delivery means sending artificial drugs into our body to inhibit gene expression and preventing cancerous cells to increase. RNAi drugs are used to cure various chronic diseases.  Right now, Research is being carried out to find right genes to cure cancer.  This market has high potential in the near future.

Few factors like Increasing incidence of chronic diseases like cancer and cardiovascular diseases, and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also fueled the growth in Middle East and Africa RNA Drug Delivery Market. But, High investments and stringent Regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market. Availability of advanced technology here compared to developed regions is low which is restraining the market’s growth.

Middle East and Africa RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into pulmonary drug delivery technology, aptamer drug delivery technology, nucleic acid drug delivery technology and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases and neurology.

Based on Geography, this market is further segmented into Middle East and Africa. CAGR is low here compared to other regions because of lack of advanced research facilities and major nations around here.

Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.